GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-α therapy
- 作者：Yu ; Ming-Lung ; Chuang ; Wan-Long ; Dai ; Chia-Yen ; Chen ; Shinn-Cherng ; Lin ; Zu-Yau ; Hsieh ; Ming-Yuh ; et. al.
- 关键词：GB virus C/hepatitis G virus RNA ; Anti-E2 antibody ; Hepatitis C virus ; Interferon
- 刊名：Antiviral Research
- 出版年：2001
- 期刊代码：7_01663542
- 类别：imm
- 出版时间：December, 2001
- 卷：52
- 期：3
- 页码：241-249
- 文件大小：95.4 K
摘要
GB virus C/hepatitis G virus (GBV-C/HGV) RNA, detected by polymerase chain reaction, and antibodies to the GBV-C/HGV envelope protein (anti-E2), detected by an enzyme-linked immunosorbent assay, were used to evaluate both the impact of GBV-C/HGV on the coexistent hepatitis C virus (HCV) infection and the course of GBV-C/HGV infection in chronic hepatitis C patients with and without interferon-α (IFN-α) treatment. Of the 162 chronic hepatitis C patients treated with INF-α, 17.9%were GBV-C/HGV RNA-positive and 18.5%anti-E2-positive (total exposure, 35.2%). Neither present nor past GBV-C/HGV infection had impact on the clinical features, HCV virological characteristics and response to IFN-α treatment in chronic hepatitis C patients. Among patients with ongoing HCV/GBV-C/HGV coinfection, 20.7%(6/29) in IFN-α-treated patients lost GBV-C/HGV RNA concomitant with anti-E2 seropositivity, which was significantly higher than 4.8%(2/42) in patients without INF-α treatment (P<0.05). Based on multivariate analyses, the significant factors associated with clearance of GBV-C/HGV viremia combined with anti-E2 seropositivity were baseline anti-E2 seropositivity and IFN-α treatment. In summary, GBV-C/HGV did not alter the course of coexistent HCV. IFN-α treatment was effective in some patients against GBV-C/HGV and might facilitate anti-E2 seroconversion in chronic hepatitis C patients with GBV-C/HGV viremia.